Binimetinib and imatinib for KIT-mutant advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests binimetinib plus imatinib in people with advanced melanoma that cannot be removed with surgery and that has a KIT mutation. It’s for melanoma that has gotten worse after standard treatment (or where standard treatment isn’t possible or tolerated).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma confirmed by lab testing (biopsy or similar sample).
- Your melanoma is Stage III or IV and can’t be treated with local surgery/radiation only.
- Your melanoma has measurable signs of disease on scans (RECIST 1.1).
- Your tumor has a KIT mutation confirmed by an approved (CLIA) lab test.
- You’re well enough to take treatment (ECOG 0–2, or similar ability level).
- You can take pills by mouth and absorb medicines well (no major swallowing or bowel absorption problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
This trial studies how doctors use encorafenib plus binimetinib for real-world care in people with BRAF V600–mutated melanoma that can’t be removed by surgery or has spread. It may help improve understanding of which patients benefit and what happens in everyday clinical practice.
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
This trial tests a combination of two targeted drugs, imatinib and trametinib, for people with advanced solid tumors that have a specific KRAS mutation (G12X). It may be an option if standard treatments have stopped working or are not available.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
Hear when a new Melanoma Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.